0001104659-17-043883.txt : 20170706
0001104659-17-043883.hdr.sgml : 20170706
20170706171841
ACCESSION NUMBER: 0001104659-17-043883
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170703
FILED AS OF DATE: 20170706
DATE AS OF CHANGE: 20170706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Protopapas Anna
CENTRAL INDEX KEY: 0001347582
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 17953202
MAIL ADDRESS:
STREET 1: MILLENNIUM PHARMACEUTICALS, INC.
STREET 2: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
a4.xml
4
X0306
4
2017-07-03
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001347582
Protopapas Anna
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2017-07-03
4
C
0
72263
A
192565
I
By Kinney/Protopapas Family Irrevocable Trust
Series B-1 Convertible Preferred Stock
2017-07-03
4
C
0
325189
0
D
Common Stock
72263
0
I
By Kinney/Protopapas Family Irrevocable Trust
Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into .22222 shares of Common Stock without payment of further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock.
These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Eva M. Jack, as Attorney-in-Fact
2017-07-06